Boston, Massachusetts--(Newsfile Corp. - October 21, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX), a biotechnology company with headquarters in Gaithersburg, Maryland. Novavax purports to be "conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19."
On October 19, 2021, after the market closed, Politico published an article, entitled "'They Rushed the Process': Vaccine Maker's woes hamper global inoculation campaign", stating that "manufacturing problems are jeopardizing billions of doses earmarked for poor and middle-income countries." The article further stated that "[a]lthough Novavax recently attested to some of its analytics and testing issues ... the company's issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter." According to the article, "the U.S. government invested $1.6 billion in Novavax in 2020-the most it devoted to any vaccine maker at the time."
On this news shares of Novavax fell $23.69 per share or 14.8% to close at $136.86 per share on October 20, 2021, on heavy volume.
If you purchased Novavax securities and sustained investment losses, and would like to discuss your legal rights, or if you wish simply to share information about the investigation, please visit: https://www.bermantabacco.com/case/novavax-inc/.
Berman Tabacco is a national law firm representing institutions and individuals in lawsuits, seeking to recoup losses caused by corporate and board misconduct and violations of the securities and antitrust laws. The firm has offices in Boston, Massachusetts and San Francisco, California.
This notice may constitute attorney advertising.
Jay Eng, Esq.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100529